On #WorldMentalHealthDay, we embrace this year's theme, "It’s Time to Prioritize Mental Health in the Workplace," underscoring the critical importance of mental well-being in professional environments. At Zymeworks, we are committed to supporting the mental and emotional health of our team by cultivating a culture of openness and care. Through our #Zymelife wellness benefits and #FlexFriday program, we take pride in creating a workplace where employees feel empowered to prioritize their #mentalhealth and thrive. Discover more about our culture: https://lnkd.in/gQfH8-Rr
Zymeworks Inc.
Biotechnology Research
Vancouver, BC 27,454 followers
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
About us
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is advancing a robust pipeline of wholly-owned product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibodies. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. Additionally, Zymeworks’ therapeutic platforms have been further leveraged through strategic partnerships.
- Website
-
http://www.zymeworks.com
External link for Zymeworks Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Type
- Public Company
- Founded
- 2003
- Specialties
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Locations
-
Primary
114 E 4th Avenue
Suite 800
Vancouver, BC V5T1G4, CA
Employees at Zymeworks Inc.
-
Daniel Dex
Senior Vice President, Corporate Secretary and General Counsel at Zymeworks Inc.
-
Derek Miller
Life sciences executive, board member, consultant and mentor with a successful track record of 25+ years across Corporate Development, Business…
-
Carlos Campoy
Board Director | Retired Public Company CFO | Audit Committee Chair | Global Business Perspective | Strategic Business Partner | Life Sciences Leader…
-
Lindsey Foulkes, PhD
VP Corporate Development
Updates
-
Join our executive leadership team on October 31 at 4:30pm ET for a conference call and webcast to discuss Q3 2024 financial results and corporate updates. See our press release for details: https://lnkd.in/eYvifpkt
-
We’re excited to announce that we’ll be presenting new preclinical data on our antibody-drug conjugate programs at the upcoming ENA Symposium on October 23-25 in Barcelona. Learn more here: https://lnkd.in/dddyg_gP #antibodydrugconjugates #drugdiscovery #ENASymp24
-
We are thrilled to share that Raffaele Colombo, PhD, our Associate Director, Medicinal Chemistry, has been selected as a 2024 PharmaVoice 100 honoree! With over 15 years of experience working in #academia, #pharma, and #biotech, focusing on the research, design, and synthesis of new payloads and drug-linkers for antibody-drug conjugates (ADCs), Dr. Colombo has been instrumental in advancing our company’s pipeline, notably leading the development of novel ADC candidates designed to balance efficacy and tolerability. Dr. Colombo’s leadership extends well beyond the lab, earning him recognition as a sought-after collaborator and speaker at major industry conferences. His contributions to Zymeworks and the ADC field have strengthened our position as a leader in multifunctional drug development, while inspiring the next generation of scientists in the life sciences. We’re proud to have Dr. Colombo as a key member of our team, whose dedication and expertise continue to push boundaries and shape the future of #cancerresearch. Learn more: https://lnkd.in/gBPUrJaV
-
We are looking forward to attending #SITC24 and presenting preclinical data on our novel 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers! Learn more: https://lnkd.in/gWHXpwpM
With over 1,400 abstract submissions, the Society for Immunotherapy of Cancer (SITC) is pleased to share the #SITC24 Regular, Young Investigator Award and Immune Engineering Abstract Titles and Authors. Browse Abstract Title & Authors: https://ow.ly/XTVi50TEihA Full abstracts are embargoed until Nov. 5 at 9 a.m. EST and will be available in a Journal for ImmunoTherapy of Cancer supplement publication.
-
Are you passionate about revolutionizing the #biotech industry and making a meaningful impact on the lives of patients with difficult-to-treat cancers and other serious diseases? If so, we invite you to join our dedicated team! As we advance a growing pipeline of novel multifunctional therapeutics through our cutting-edge antibody-drug conjugates and multispecific antibody technology platforms, we are looking for talented individuals across various fields—clinical development, science, regulatory, corporate, and technical operations. Explore our current opportunities: https://lnkd.in/eiyDybK3 #WeAreHiring #BiotechJobs #OncologyJobs #BiotechCareers #CancerResearchJobs #LifeSciencesCareers #VancouverBiotech #JoinOurTeam #BiotechTalent
-
We are currently seeking a Vice President of #InformationTechnology to join our team. This individual will drive our global #IT strategy to support our clinical development and research efforts. The role will ensure that our technology infrastructure aligns with and accelerates our mission to make a meaningful difference for people around the world impacted by difficult-to-treat cancers and other serious diseases. If you’re passionate about leveraging technology to make an impact, learn more about the position: https://lnkd.in/eiyDybK3 #WeareHiring #BiotechJobs #OncologyJobs #BiotechCareers #CancerResearchJobs #LifeScienceCareers #ITJobs #Hiring #OpentoWork #Recruitment #InformationTechnologyJobs #TechnologyJobs
-
We had an incredible time at our annual philanthropic event across our hubs in Vancouver, Bellevue, and Redwood City! Thank you to everyone who joined us in assembling more than 1,400 care kits for patients at BC Children's Hospital, Seattle Children's Hospital, and Lucile Packard Children's Hospital. These care kits provide comfort and support to children and families during challenging times, reflecting our dedication to giving back to the communities we serve. As we work to develop novel, multifunctional therapeutics for difficult-to-treat cancers and other serious diseases, we are equally proud of our team's commitment to making a meaningful difference through both research and volunteer efforts. Our collective impact extends beyond the lab, and we are honored to contribute to causes that align with our mission of improving lives.
-
September 30 marks the National Day for Truth and Reconciliation, a day dedicated to honoring the resilience, dignity, and strength of those affected by Indigenous residential schools, including survivors, victims, and their families and communities. Today, we stand with our Canadian colleagues to raise awareness about the impact of Canada’s colonial history on Indigenous communities. Let’s honor this day by deepening our understanding and supporting the ongoing journey towards truth and reconciliation. Explore and celebrate the rich and diverse cultures, voices, and stories of First Nations, Inuit, and Métis peoples here: https://lnkd.in/gHrRzxkc
-
Today on #WorldCancerResearchDay, we proudly stand with the global scientific community to underscore the critical role that research plays in improving cancer survival rates and enhancing the quality of life for patients and their families. At Zymeworks, we are deeply committed to the belief that continued research, innovation, and scientific advancement can profoundly impact the lives of cancer patients. As we advance our pipeline of multifunctional therapeutics, we honor our exceptional team of researchers, experts, and partners who are dedicated to harnessing the potential of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) to address high unmet needs in the treatment of difficult-to-treat cancers. Together, we are driving innovation within #cancerresearch and remain unwavering in our commitment to making a meaningful difference. #AntibodyDrugConjugates #MultifunctionalTherapeutics #Biotech #DrugDevelopment #DrugDiscovery #CancerAwareness #Oncology #ResearchandDevelopment